APA (7th ed.) Citation

GE, G., Z, M., B, M., PB, G., LG, B., G, C., . . . L, C. (2014). Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: Unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. The Lancet. Infectious diseases, 14(5), 388. https://doi.org/10.1016/S1473-3099(14)70020-9

Chicago Style (17th ed.) Citation

GE, Gray, et al. "Recombinant Adenovirus Type 5 HIV Gag/pol/nef Vaccine in South Africa: Unblinded, Long-term Follow-up of the Phase 2b HVTN 503/Phambili Study." The Lancet. Infectious Diseases 14, no. 5 (2014): 388. https://doi.org/10.1016/S1473-3099(14)70020-9.

MLA (9th ed.) Citation

GE, Gray, et al. "Recombinant Adenovirus Type 5 HIV Gag/pol/nef Vaccine in South Africa: Unblinded, Long-term Follow-up of the Phase 2b HVTN 503/Phambili Study." The Lancet. Infectious Diseases, vol. 14, no. 5, 2014, p. 388, https://doi.org/10.1016/S1473-3099(14)70020-9.